GSK_ Annual_Report_2021-22

Notes to the Consolidated Financial Statements for the year ended March 31, 2022 225 Note 16 : Assets classified as held for sale ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Freehold Land and Building 9.60 9.60 Plant and Machinery (Refer Note (a) below) 1.63 1.63 Assets at Vemgal location (Refer Note (b) below) - 180,00.61 11.23 180,11.84 Notes:- (a) The amount includes Plant and Machinery from Mysore and Bangalore site held for sale. (b) Assets at Vemgal location held for sale during the previous year ended March 31, 2021 consequent to the binding sale agreement entered into by the Group .The Group has received all relevant statutory and other approvals during the year and transaction has been concluded in December 2021. Note 17 : Equity Share Capital ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Authorised 18,00,00,000 (March 31, 2021: 18,00,00,000) equity shares of ` 10 each 180,00.00 180,00.00 Issued 16,94,15,420 (March 31, 2021: 16,94,15,420) equity shares of ` 10 each 169,41.54 169,41.54 Subscribed and Paid-Up 16,94,06,034* (March 31, 2021: 16,94,06,034) equity shares of ` 10 each, fully paid up 169,40.60 169,40.60 169,40.60 169,40.60 * excludes 9,386 (March 31, 2021: 9,386) equity shares of ` 10 each of the Group (3,352 equity shares of ` 10 each of erstwhile Burroughs Wellcome (India) Limited) held in abeyance. As at March 31, 2022 As at March 31, 2021 Number of Shares ` in lakhs Number of Shares ` in lakhs a) Reconciliation of the number of shares Balance at the beginning of the year 16,94,06,034 169,40.60 16,94,06,034 169,40.60 Balance at the end of the year 16,94,06,034 169,40.60 16,94,06,034 169,40.60 b) Rights, preferences and restrictions attached to equity shares: The Group has one class of equity shares having a par value of ` 10 per share. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Group after distribution of all preferential amounts, in proportion to their shareholding. c) Shares held by promoters of Group Sr. No. Promoter's Name FY 2021-22 % change during the year No. of Shares % of total shares (i) Glaxo Group Limited, U.K. 6,09,70,500 35.99% - (ii) Eskaylab Limited, U.K. 1,17,60,000 6.94% - (iii) Burroughs Wellcome International Limited 67,20,000 3.97% - (iv) GlaxoSmithKline Pte Limited, Singapore 4,76,04,024 28.10% -